In an important move for the healthcare sector, Latham & Watkins announced the addition of two new partners to their healthcare practice in Washington. Bloomberg Law reports that renowned lawyers Jennifer Bragg and Bill McConagha are set to join the firm.
Having built a significant legal career, Bragg is renowned for advising companies on compliance and investigations initiated by governmental authorities such as the Food and Drug Administration (FDA) and the Department of Justice. Additionally, she boasts an impressive portfolio of advising pharmaceutical companies, medical device manufacturers, and other FDA-regulated entities on complex transactional matters.
Bringing another dimension to the firm’s healthcare expertise, McConagha is highly experienced in advising companies on the lifecycle of FDA-regulated products. His specializations range from drugs to medical devices, complex biologics, food products, and novel tobacco products. The breadth of his expertise also covers client counsel on pre-market development, providing a comprehensive understanding of all regulatory aspects.
With these new additions, Latham & Watkins shows a continued investment in the healthcare practice. The in-depth regulatory knowledge and experience both Bragg and McConagha bring to the firm will certainly enhance its service offering to clients navigating the expansive and often complex FDA-regulated landscape.
For more information on their appointments, visit the firm’s official announcement.